Table 1.
Treatment strategies for localized (stage IE/IIE) ENKTL.
| Regimen | Treatment | N | ORR/CR (%) | OS/PFS (%) | Grade III/IV neutropenia (%) |
|---|---|---|---|---|---|
| Concurrent therapy | |||||
| DeVIC [38, 39] | Simultaneous RT 50 Gy+DeVIC×3 | 33 | 77/76 | 70/63 (5-yr) | 91 |
| VIPD [40] | CCRT (weekly cisplatin+RT 40–50.8 Gy) | 30 | 83/80 | 86/85 (3-yr) | 47 |
| →VIPD×3 | |||||
| VIDL [41] | CCRT (weekly cisplatin+RT 40–44Gy) | 30 | 90/87 | 60/73 (5-yr) | 80 |
| →VIDL×3 | |||||
| MIDDLE [42] | CCRT (weekly cisplatin, L-asparaginase×3+RT 36–44 Gy)→MIDDLE×2 | 28 | 86/82 | 82/74 (3-yr) | 91 |
| GDP [43] | CCRT (weekly cisplatin+IMRT 56 Gy)→GDP×3 | 32 | 91/84 | 88/84 (3-yr) | 41 (leukopenia) |
| MPVIC-P [44] | Simultaneous RT 56 Gy+intra-arterial | 12 | 100/100 | 100/100 (5-yr) | 33 |
| MPVIC-P | |||||
| Sequential therapy | |||||
| SMILE [44] | SMILE→RT→SMLIE | 17 | NA/82 | NA | NA |
| LVP [32, 47] | LVP→IFRT→LVP | 26 | 89/81 | 65/64 (5-yr) | 31 (grade 3) |
| GELOX [31, 48] | GELOX→IFRT | 27 | 96/74 | 86/86 (2-yr) | NA |
| P-GEMOX [49] | P-GEMOX×2→RT 56 Gy | 33 | 94/80 | 83/77 (2-yr) | 33.3 |
| DICE-L [50] | DICE-L×3→RT 45 Gy | 27 | NA/91 | 89/82 (5-yr) | 4.4 (leukopenia) |
Abbreviations: CR, complete remission; ENKTL, Extranodal NK/T cell lymphoma; NA, not available; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial remission; RT, radiotherapy.